BioMarin Submits Drisapersen MAA to EMA for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
June 08, 2015 at 08:37 AM EDT
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today the submission of a Marketing Authorization Application (MAA) to the ...